Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 16
SponsorAssiut University
About this trial
Liver dysfunction is a well-documented complication in patients with congenital heart disease (CHD). The mechanisms leading to hepatic dysfunction may be multifactorial. Key risk factors for liver dysfunction in CHD include prolonged hypoxemia, high venous pressure, and prolonged duration of heart disease.
While global studies have extensively explored this association, the prevalence of liver dysfunction in CHD varies, with studies reporting hepatic fibrosis in 30-40% of Fontan patients, while regional data, particularly from Egypt, remain limited.
In this research we aim to determine the prevalence of biochemical and radiological hepatic abnormalities in pediatric CHD patients attending Assiut University Children's Hospital.
Eligibility criteria
Qualifiers
Confirmed pediatric CHD patients attending Assiut University Children's Hospital.
Age: from birth up to 16 years old.
Disqualifiers
Patients with primary liver disease.
Recent cardiac surgery (<3 m) (to exclude acute postoperative liver injury).
Active systemic infection/sepsis (to avoid confounding liver enzyme elevations).
Trial design
Treatments tested in this trial
- Ultrasonography
- Blood Sampling
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov